Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MLN7243 in Advanced Solid Tumors
NCT02045095Phase 1Terminated
- Sponsor
- Millennium Pharmaceuticals
- Start
- Jan 2014
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of TAK-243 in solid tumor (advanced stage), sponsored by Millennium Pharmaceuticals. Primary endpoints: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), Number of Participants With Laboratory Related TEAEs by System Organ Class (SOC) and 4 more. Started Jan 2014; status: terminated.
02
Drugs
TAK-243
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02045095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02045095.